A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

PROCEPT BioRobotics Corporation PRCT

Promising (early) broader-coverage candidate · PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology.

On FrontierLab's discovery record since 2026-08-12 (9 days ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-13), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)	22.7%
Gross margin	63.7%
Gross profits / assets	0.45
Rule of 40	-11.2
Net margin	-33.9%
Cash runway (months)	24.3
PEG	—
Price / sales	3.6

Quality checklist

✓ Revenue growth — 22.7% (pass ≥ 20%)
✓ Capital efficiency
✓ Gross margin — 63.7% (pass ≥ 60%)
~ Gross-margin trend — 0.1 (pass ≥ 2)
✓ Share dilution — 1.9%

Fundamentals — snapshot as of 2026-08-13

Stage	Early
Share issuance (YoY)	1.9% · modest issuance
Moat	—
TAM	—
P/E (trailing)	—
EPS (trailing)	$-1.94
Burn multiple	0.3
Gross-margin trend (pts)	0.1
Cash / assets	0.48
Net debt / EBITDA	—
Statements as of	Q2 FY2026 · filed 2026-08-05

Momentum context — a snapshot from 2026-08-13, not current

Price at surface	$21.25 (as of 2026-08-13)
52-week range	$16.665 – $42.705
% off 52-wk high	-50.2%
RSI (14)	56
Relative volume	0.6×

Risk flags

Burning cash — operating margin is negative.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-08-13 (end-of-day). How grades are computed →